天目药业子公司收到药品再注册批准通知书

Core Viewpoint - Tianmu Pharmaceutical (600671.SH) has received approval from the Anhui Provincial Drug Administration for the re-registration of several drugs, including Liuwei Dihuang Wan, which ensures the stability and continuity of the company's drug production and sales qualifications [1] Group 1 - The approval of the re-registration notification for the drugs positively impacts the company's future production, sales, and promotion activities [1]